These therapies target neurotransmitter systems, neuroplasticity, and mitochondrial function within the brain
Notably, astaxanthin improves total antioxidant capacity (TAC) in follicular fluid but exerts inconsistent effects on catalase (CAT), malondialdehyde (MDA), or superoxide dismutase (SOD) levels
Employers indicated the following coverage for GLP-1 drugs: 56% provide coverage for diabetes only (down from 66% in 2024) 31% provide coverage for both diabetes and weight loss (up from 17% in 2024)
Abstract Purpose Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained considerable media attention, but there is limited knowledge about those receiving the drugs
The safest option is the one matched to your body, not to gendered packaging
Weight Loss Results: Head-to-Head Data Semaglutide Clinical Trial Results The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the most comprehensive dataset for any anti-obesity medication: STEP 1 (Wilding et al., 2021, NEJM ): 1,961 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities Semaglutide 2.4 mg weekly vs
